2016
DOI: 10.1016/j.radonc.2016.09.014
|View full text |Cite
|
Sign up to set email alerts
|

Hemi-gland focal low dose rate prostate brachytherapy: An analysis of dosimetric outcomes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
12
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 17 publications
(13 citation statements)
references
References 22 publications
0
12
0
Order By: Relevance
“…Four studies (4.8%) related to preclinical research (IDEAL phase 0). The 43 remaining original research studies that applied IDEAL were mapped to the corresponding IDEAL stage: IDEAL with nine (20.9%), 27 (62.8%), four (9.3%), 0 (0%), and three (7.0%) publications, respectively .…”
Section: Resultsmentioning
confidence: 99%
“…Four studies (4.8%) related to preclinical research (IDEAL phase 0). The 43 remaining original research studies that applied IDEAL were mapped to the corresponding IDEAL stage: IDEAL with nine (20.9%), 27 (62.8%), four (9.3%), 0 (0%), and three (7.0%) publications, respectively .…”
Section: Resultsmentioning
confidence: 99%
“…The divergent behaviour in PSA kinetics between temperature‐based ablative therapies and PB may be explained by their mechanism of action. 125 I seed implants deliver 87.5% of radiation energy from isotope decay in the first 6 months and the ‘untreated’ HG also receives a (reduced) radiation dose . Theoretically, temperature‐based therapies are not expected to affect the untreated HG.…”
Section: Discussionmentioning
confidence: 99%
“…A median (interquartile range [IQR]) of 54 (48–60) 125 I seeds were implanted per patient with a median (IQR) source activity of 0.533 (0.533–0.538) U. The dosimetric approach aimed to treat the entire affected HG even if some seeds were implanted in the contralateral side to ensure optimal dosimetry . The procedure took ~40 min and post‐implant dosimetry was obtained within the next 18 h by a CT scan.…”
Section: Methodsmentioning
confidence: 99%
“…There is also some early interest in mpMRI imaging to guide focal brachytherapy, with implants delivering dose to only the visible tumor lesion or involved hemi-gland, as a means to minimize treatment-related toxicity ( 14 ). While early reports of these treatments suggest they are technically feasible and can reduce doses to nearby organs at risk, their long-term oncologic efficacy remains unproven ( 120 - 122 ).…”
Section: New Developments In Ldr Prostate Brachytherapymentioning
confidence: 99%